Gameto has shared an update. The company announced that its R&D Chief of Staff, Alexander Noblett, PhD, will present a booth talk at ASRM 2025 titled “Reimagining Menopause Treatment with a Steroidogenic, Hormone-Sensitive Ovarian Implant.” The session will focus on Gameto’s Ameno program, which is developing an ovarian implant leveraging engineered ovarian-like cells and controlled androgen release as a novel approach to menopause treatment. The Ameno program previously secured funding from the U.S. Advanced Research Projects Agency for Health (ARPA-H) under its Sprint for Women’s Health Initiative.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
For investors, this update underscores Gameto’s progress in advancing a differentiated women’s health platform with non-dilutive support from a prominent federal funding source. The ARPA-H backing signals external validation of the scientific and clinical potential of the Ameno program, which may improve the company’s ability to attract additional capital or strategic partners. While the financial terms of the funding and development timeline are not disclosed, a successful advancement of this implant-based menopause therapy could position Gameto within a high-need, large addressable market where current treatment options have limitations. Participation and visibility at ASRM 2025 may further enhance Gameto’s profile among clinicians and industry stakeholders, potentially supporting future commercialization and licensing opportunities if clinical data prove favorable.